Pacira BioSciences (NASDAQ:PCRX) Given "Sell (D)" Rating at Weiss Ratings

Key Points

• Pacira BioSciences has been given a "sell (D)" rating by Weiss Ratings, while other analysts have mixed opinions, with some rating it as a "buy" and others a "hold."
• Shares of Pacira BioSciences opened at $23.41, with a market capitalization of $1.05 billion and a noted 1-year high of $27.64.
• Despite a net margin of -18.08%, Pacira reported earnings per share of $0.74, surpassing analysts' expectations for the quarter.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report)'s stock had its "sell (d)" rating restated by analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

A number of other research analysts have also weighed in on PCRX. Truist Financial raised Pacira BioSciences from a "hold" rating to a "buy" rating and set a $30.00 price objective on the stock in a report on Friday, July 25th. Zacks Research raised Pacira BioSciences from a "strong sell" rating to a "hold" rating in a report on Thursday, August 14th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $33.40.

Pacira BioSciences Trading Down 0.9%

Shares of PCRX stock opened at $23.41 on Wednesday. The business's fifty day moving average price is $25.38 and its 200 day moving average price is $24.87. Pacira BioSciences has a 1-year low of $15.16 and a 1-year high of $27.64. The firm has a market capitalization of $1.05 billion, a PE ratio of -8.42 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.38 and a quick ratio of 1.91.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.74 earnings per share for the quarter, topping analysts' consensus estimates of $0.73 by $0.01. Pacira BioSciences had a positive return on equity of 13.29% and a negative net margin of 18.08%.The firm had revenue of $181.10 million for the quarter, compared to analyst estimates of $183.11 million. During the same quarter in the prior year, the company posted $0.96 earnings per share. Pacira BioSciences's quarterly revenue was up 1.7% on a year-over-year basis. Pacira BioSciences has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Pacira BioSciences will post 2.41 EPS for the current fiscal year.

Insider Activity

In other news, Director Marcelo Bigal sold 4,912 shares of the company's stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $23.67, for a total value of $116,267.04. Following the sale, the director directly owned 11,393 shares in the company, valued at $269,672.31. This represents a 30.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.40% of the stock is owned by corporate insiders.

Institutional Trading of Pacira BioSciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Pacira BioSciences in the first quarter valued at $51,000. US Bancorp DE lifted its position in shares of Pacira BioSciences by 31.0% in the first quarter. US Bancorp DE now owns 2,270 shares of the company's stock valued at $56,000 after acquiring an additional 537 shares in the last quarter. Brooklyn Investment Group lifted its position in shares of Pacira BioSciences by 372.2% in the first quarter. Brooklyn Investment Group now owns 2,238 shares of the company's stock valued at $56,000 after acquiring an additional 1,764 shares in the last quarter. Wealthquest Corp purchased a new stake in shares of Pacira BioSciences in the first quarter valued at $59,000. Finally, Strs Ohio purchased a new stake in shares of Pacira BioSciences in the first quarter valued at $75,000. 99.73% of the stock is currently owned by hedge funds and other institutional investors.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.